Business Wire

MASIMO

Share
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical Patients

Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the British Journal of Neurosurgery in which Dr. Ankita Dey and colleagues at institutions in Bathinda and Pondicherry, India evaluated the use of noninvasive, continuous Masimo PVi®, as part of goal-directed fluid therapy (GDFT), to guide intraoperative fluid administration during neurosurgery – the first study to evaluate PVi in this surgical scenario – by comparing it to a parameter obtained invasively, stroke volume variation (SVV). The researchers concluded that “PVi and SVV are equally effective for guiding intraoperative goal-directed fluid therapy in adult neurosurgical patients scheduled for elective craniotomy for supratentorial brain tumors. However, PVi, being a noninvasive parameter, may be preferable.”1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005560/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Masimo Root® with PVi® (Photo: Business Wire)

Noting the value of GDFT for neurosurgical patients in particular, but that most of the dynamic parameters traditionally used to guide GDFT, such as SVV, are invasive, requiring the use of an intra-arterial catheter (an arterial line, or “A-line”), which is associated with a variety of complications, the researchers sought to determine whether a noninvasive parameter, PVi, whose measurements are derived from the photoplethysmographic waveform, might serve as a reliable predictor of fluid responsiveness in such a population. PVi, or pleth variability index, is a measure of the variations in perfusion index over the respiratory cycle, and is indicated as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.

To test their hypothesis, the researchers randomly divided 60 adult patients undergoing elective craniotomy into two groups: one whose intraoperative fluid administration was guided by PVi (n=29) and the other, by SVV (n=31). In the PVi group, patients were monitored using Masimo Radical-7® Pulse CO-Oximeters® with noninvasive pulse oximetry fingertip sensors. In the SVV group, SVV was invasively measured using an Edwards Lifesciences Vigileo/FloTrac device connected to a cannulated radial artery. The researchers compared the total amount of intravenous fluid administered during surgery, as well as serum lactate and serum creatinine levels at pre-determined time points, the brain relaxation score at dural opening and closure, and correlation between PVi and SVV values. They also compared duration of mechanical ventilation and length of hospital stay.

As noted in the table below, the researchers found that the volume of fluid administered intraoperatively was significantly higher in the SVV group. The other parameters and outcomes they measured were comparable between the two groups: serum lactate, serum creatinine, brain relaxation score, duration of mechanical ventilation, and length of hospital stay, as noted below. The researchers also observed “a moderate to strong correlation between SVV and PVi at corresponding points of time during the intraoperative period. This suggests that PVi, derived noninvasively from the pulse oximetry waveform, is a reliable indicator of fluid responsiveness.”

Outcome

PVi group

SVV group

p-Value

Volume of fluid administered

2139.3 ± 898.6 mL (mean)

3208.3 ± 1836.2 mL (mean)

0.005

Serum lactate level, over time

Ranging from 1.59 ± 0.91 to 2.73 ± 1.18

Ranging from 1.79 ± 0.97 to 2.44 ± 0.88

Ranging from 0.55 to 0.82

Serum creatinine level, over time

Ranging from 0.64 ± 0.14 to 0.66 ± 0.15 mg/dL

Ranging from 0.64 ± 0.17 to 0.71 ± 0.21 mg/dL

Ranging from 0.23 to 0.86

Brain relaxation score

2 (1-3) at dural opening, 2 (12) at dural closing (median)

2 (1-4) at dural opening and closing (median)

0.49 (opening)

0.33 (closing)

Duration of mechanical ventilation

19.09 ± 15.9 hours (mean)

 

27.9 ± 15.9 hours (mean)

0.1

Length of hospital stay

12.6 ± 19.26 days (mean)

16.4 ± 26.8 days (mean)

0.53

The researchers concluded, “Based on the findings of our study, we conclude that PVi and SVV are equally effective for guiding intraoperative goal directed fluid therapy in adult neurosurgical patients scheduled for elective craniotomy for supratentorial brain tumors. However, PVi, being a noninvasive parameter, may be preferable.” They continued, “The two groups in our study were comparable with respect to serum creatinine and serum lactate measured at predetermined time points intraoperatively and post operatively. The two groups were also comparable with respect to brain relaxation scores at dural opening and dural closure. There was moderate to strong correlation between SVV and PVi at corresponding time points intraoperatively. The duration of mechanical ventilation and the length of hospital stay was also comparable between the two groups.”

Joe Kiani, Founder and CEO of Masimo, said, “We introduced PVi in 2007. It was the first and still is the only noninvasive way of measuring fluid responsiveness in mechanically ventilated patients at a fraction of the cost of invasive methods and without risk of invasive procedures to the patient. Since then, over 100 studies have shown that PVi or PVi in combination with our noninvasive hemoglobin technology, SpHb®, has made a tremendous contribution to patient care.2 This latest study adds to the evidence that PVi can be used to help clinicians manage the fluid levels of their patients without invasive catheters.”

In the US, PVi is FDA 510(k) cleared as a noninvasive dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients. Accuracy of PVi in predicting fluid responsiveness is variable and influenced by numerous patient, procedure and device related factors. PVi measures the variation in the plethysmography amplitude but does not provide measurements of stroke volume or cardiac output. Fluid management decisions should be based on a complete assessment of the patient’s condition and should not be based solely on PVi.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,10 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.11 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and the Masimo W1™ watch. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Dey A, Bidkar PU, Swaminathan S, Kumari M, Joy JJ, Balasubramanian M, Bhimsaria S. Comparison of two techniques of goal-directed fluid therapy in elective neurosurgical patients – a randomized controlled study. Br J Neuosurgery. 3 Feb 2023. DOI: 10.1080/02688697.2023.2173722/
  2. Published clinical studies on PVi can be found on our website at http://www.masimo.com.
  3. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  4. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  5. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  6. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  7. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  8. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  9. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  10. Estimate: Masimo data on file.
  11. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo PVI®, SpHb®, and Radical-7®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo PVi, SpHb, and Radical-7, contribute to positive clinical outcomes and patient safety; risks that the researchers’ conclusions and findings may be inaccurate; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005560/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Access Advance Welcomes Global Technology Leaders as Licensees and Licensors to New Video Distribution Patent Pool2.7.2025 02:00:00 CEST | Press release

Access Advance LLC ("Advance") today announced the inaugural roster of licensees and licensors for its Video Distribution Patent ("VDP") Pool, marking a significant milestone in the program's rapid market adoption since its January announcement. The participation of major global companies heavily involved in video codec technology demonstrates strong industry support for the comprehensive licensing solution covering HEVC, VVC, VP9, and AV1 codecs. The VDP Pool has successfully attracted a group of licensees/licensors including ByteDance, Kuaishou, NTT Docomo, and Tencent. This represents the beginning of what Access Advance expects to be widespread adoption among content streaming providers seeking simplified codec licensing. The licensees’ participation provides immediate access to the wide-ranging patent portfolio while benefiting from the fixed tiered pricing structure designed to scale with business size. "We're pleased to welcome ByteDance, Kuaishou, NTT Docomo and Tencent as our

Intralot S.A. to Acquire Bally’s International Interactive Business in a Transaction that Creates a Global Gaming Technology and Services Company in Lottery and Digital Online Gaming Markets1.7.2025 21:10:00 CEST | Press release

Intralot S.A. to Remain Listed on the Athens Stock ExchangeTransaction Enterprise Value of €2.7 Billion Intralot S.A. (ATSE: INLOT) (“Intralot”) and Bally’s Corporation (NYSE: BALY) (“Bally’s”) today announced that their respective Boards of Directors approved their entry into a definitive transaction agreement (“Transaction Agreement”) pursuant to which Intralot will acquire Bally’s International Interactive business (the “International Interactive Business”) in a cash-and-shares transaction that values the International Interactive Business at an enterprise value of €2.7 billion (the “Transaction”). The consideration for the acquisition of the International Interactive Business will comprise a combination of cash paid by Intralot and newly issued shares delivered by Intralot to Bally’s, as more specifically detailed below. As part of the Transaction, Intralot expects to refinance part of its existing debt facilities and Bally’s also expects to repay secured debt from the cash proceed

Valeo Foods Group Acquires Melegatti Cakes Expanding the Italian Bakery Portfolio1.7.2025 18:21:00 CEST | Press release

Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the assets of an Italian panettone, pandoro and croissant producer, Melegatti 1894 S.p.A.This acquisition is another step forward in Valeo Foods Groups’ strategy to expand its baked sweet treats portfolio, and reinforces Valeo’s commitment to bringing authentic Italian confections and established regional brands to a wider international audience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702677156/en/ Melegatti Founded in 1894 in Verona, Melegatti has a strong reputation for artisanal cakes - particularly pandoro, panettone and filled croissants - traditional recipes, and a rich Italian heritage, Melegatti has a proud legacy founded on family values, craftsmanship, and a passion for quality. “We are excited to welcome Melegatti into the Valeo Foods Group,” said Ronald Kers, Group CEO. “This acquisition

PUMA and Borussia Dortmund Extend Partnership1.7.2025 18:18:00 CEST | Press release

Sports company PUMA has extended its long-standing partnership with Borussia Dortmund, and will continue to create products that cater to BVB’s many passionate fans around the world and match the club’s dynamic, fast paced style of football. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701775493/en/ Sports company PUMA has extended its long-standing partnership with Borussia Dortmund, and will continue to create products that cater to BVB’s many passionate fans around the world and match the club’s dynamic, fast paced style of football. Since the start of their partnership in the 2012/13 season, BVB has celebrated many successes, such as reaching the finals of the 2012/13 and 2023/24 UEFA Champions League and winning the 2016/17 and 2020/21 German DFB Cup. The club is currently participating in the FIFA Club World Cup, where it has already reached the round of 16. BVB continues to set the standard in European football w

Gogo Galileo HDX Coming to Cessna Citation Jet Models1.7.2025 17:00:00 CEST | Press release

Expected FAA Supplemental Type Certification in late 2025 Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. The global Low Earth Orbit (LEO) solution allows customers to enjoy one of the best possible in-flight connectivity and aviation experiences, no matter where their journey takes them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701750049/en/ Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. (Photo: Textron Aviation) By offering Gogo Galileo HDX as an aftermarket upgrade, the Textron Av

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye